Pfizer says COVID-19 vaccine is 100% effective in teens ages 12-15

Listen
Text
  • Small
  • Medium
  • Large

Pfizer released data Nov. 22 showing its COVID-19 vaccine was 100 percent effective at preventing disease among recipients ages 12-15, measured from seven days to four months after they received their second shot.

The data comes from a phase 3 clinical trial involving 2,228 participants. No serious side effects were observed.

"As the global health community works to increase the number of vaccinated people around the world, these additional data provide further confidence in our vaccine's safety and effectiveness profile in adolescents. This is especially important as we see rates of COVID-19 climbing in this age group in some regions, while vaccine uptake has slowed," Pfizer CEO Albert Bourla, PhD, said in a statement. "We look forward to sharing these data with the FDA and other regulators."

Pfizer will use the data to support its planned submission for the vaccine's full FDA approval for teenage recipients. 

The FDA granted emergency use authorization for the vaccine's use in children ages 12-15 in May. The agency granted full approval for the vaccine's use in people ages 16 and older in August.

 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars